By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TG Therapeutics, Inc. 

787 Seventh Avenue
48th Floor
New York  New York  10019  U.S.A.
Phone: 212-554-4484 Fax: 212-554-4531


SEARCH JOBS


Industry
Pharmaceutical






Company News
TG Therapeutics, Inc. (MHA) Announces Appointment Of Kenneth Hoberman To Board Of Directors 12/17/2014 7:45:45 AM
TG Therapeutics, Inc. (MHA) Release: Preliminary Data From Ongoing Phase I/II Dose Escalation Study Of TG-1101 (Ublituximab) In Combination With TGR-1202 In Heavily Pre-Treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity And Safety 12/9/2014 10:49:31 AM
TG Therapeutics, Inc. (MHA) Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 12/9/2014 10:37:35 AM
TG Therapeutics, Inc. (MHA) Release: Interim Data From Phase 1 Dose Escalation Clinical Trial Of TGR-1202, The Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity And Lack Of Hepatic Toxicity In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 12/8/2014 7:24:52 AM
TG Therapeutics, Inc. (MHA) Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib (Imbruvica) For Patients With Select B-Cell Malignancies 12/1/2014 10:32:34 AM
TG Therapeutics, Inc. (MHA) To Present At The 2014 Deutsche Bank (DB) BioFEST Conference 11/26/2014 11:52:36 AM
TG Therapeutics, Inc. (MHA) Announces Third Quarter 2014 Financial Results and Business Update 11/11/2014 8:06:27 AM
TG Therapeutics, Inc. (MHA) To Host Conference Call On Third Quarter 2014 Financial Results And Business Update 11/10/2014 7:42:10 AM
TG Therapeutics, Inc. (MHA) Announces Data Presentations At The Upcoming 56th American Society of Hematology Annual Meeting 11/6/2014 10:37:55 AM
TG Therapeutics, Inc. (MHA) Announces Exercise Of License Option For Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202 9/23/2014 8:14:36 AM
12345678910...
//-->